Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials
Chansky, Kari, Rubinstein, Larry , Catalano, Paul J. , Crowley, John, Philip, Philip A. , LeBlanc, Michael , Seymour, Lesley , Ivy, S. Percy , Alberts, Steven R. , Rubinstein, Larry V

Clinical Cancer Research | June 10, 2014 | Volume: 20 | Issue: 16 | Pages: 4176-4185

10.1158/1078-0432.ccr-13-2024 | PMID 24914040 Get It

AbstractWe compiled and analyzed a database of cooperative group trials in advanced pancreatic cancer to develop historical benchmarks for overall survival (OS) and progression-free survival (PFS). Such benchmarks are essential for evaluating new therapies in a single-arm setting. The analysis included patients with untreated metastatic pancreatic cancer receiving regimens that included gemcitabine, between 1995 and 2005. Prognostic baseline factors were selected by their significance in Cox regression analysis. Outlier trial arms were identified by comparing individual 6-month OS and PFS rates against the entire group. The dataset selected for the generation of OS and PFS benchmarks was then tested for intertrial arm variability using a logistic-normal model with the selected baseline prognostic factors as fixed effects and the individual trial arm as a random effect. A total of 1,132 cases from eight trials qualified. Performance status and sex were independently significant for OS, and performance status was prognostic for PFS. Outcomes for one trial (NCCTG-034A) were significantly different from the other trial arms. When this trial was excluded, the remaining trial arms were homogeneous for OS and PFS outcomes after adjusting for performance status and sex. Benchmark values for 6-month OS and PFS are reported along with a method for using these values in future study design and analysis. The benchmark survival values were generated from a dataset that was homogeneous between trials. The benchmarks can be used to enable single-arm phase II trials using a gemcitabine platform, especially under certain circumstances. Such circumstances might be when a randomized control arm is not practically feasible, an early signal of activity of an experimental agent is being explored such as in expansion cohorts of phase I studies, and in patients who are not candidates for combination cytotoxic therapy. Clin Cancer Res; 20(16); 4176–85. ©2014 AACR.
Effect of Aging on Human Circulatory System in Normotensive Healthy Subjects
Lin, Mike, Lin, Shoa-Lin, Wang, Kuei-Liang, Kuo, Hsien‐Wen , Tak, Tahir

International Journal of Angiology | June 9, 2014 | Volume: 23 | Issue: 04 | Pages: 233-242

10.1055/s-0034-1374735 | PMID 25484554 Get It

Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative
Weiner, Michael W. , Veitch, Dallas P. , Aisen, Paul, Petersen, Ronald C. , Jagust, William, Trojanowski, John Q. , Shaw, Leslie M. , Saykin, Andrew J. , Harvey, Danielle , Pacifico, Anthony, Sheline, Yvette I. , Yaffe, Kristine , Mohlenoff, Brian, Hayes, Jacqueline , Neylan, Thomas C. , Grafman, Jordan Henry , Jack, Clifford R. , Green, Robert C. , Toga, Arthur W. , Friedl, Karl E. , Saykin, Andrew J , Harvey, Danielle J

Alzheimer's & Dementia | June 9, 2014 | Volume: 10 | Issue: 3S | Pages: No page available

10.1016/j.jalz.2014.04.005 | PMID 24924673 Get It

AbstractBoth traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) are common problems resulting from military service, and both have been associated with increased risk of cognitive decline and dementia resulting from Alzheimer's disease (AD) or other causes. This study aims to use imaging techniques and biomarker analysis to determine whether traumatic brain injury (TBI) and/or PTSD resulting from combat or other traumas increase the risk for AD and decrease cognitive reserve in Veteran subjects, after accounting for age. Using military and Department of Veterans Affairs records, 65 Vietnam War veterans with a history of moderate or severe TBI with or without PTSD, 65 with ongoing PTSD without TBI, and 65 control subjects are being enrolled in this study at 19 sites. The study aims to select subject groups that are comparable in age, gender, ethnicity, and education. Subjects with mild cognitive impairment (MCI) or dementia are being excluded. However, a new study just beginning, and similar in size, will study subjects with TBI, subjects with PTSD, and control subjects with MCI. Baseline measurements of cognition, function, blood, and cerebrospinal fluid biomarkers; magnetic resonance images (structural, diffusion tensor, and resting state blood‐level oxygen dependent (BOLD) functional magnetic resonance imaging); and amyloid positron emission tomographic (PET) images with florbetapir are being obtained. One‐year follow‐up measurements will be collected for most of the baseline procedures, with the exception of the lumbar puncture, the PET imaging, and apolipoprotein E genotyping. To date, 19 subjects with TBI only, 46 with PTSD only, and 15 with TBI and PTSD have been recruited and referred to 13 clinics to undergo the study protocol. It is expected that cohorts will be fully recruited by October 2014. This study is a first step toward the design and statistical powering of an AD prevention trial using at‐risk veterans as subjects, and provides the basis for a larger, more comprehensive study of dementia risk factors in veterans.
Anterior spinal artery infarction causing man-in-the-barrel syndrome
Flanagan, Eoin P. , McKeon, Andrew , Weinshenker, Brian G. , Flanagan, E P , McKeon, Andrew

Neurology Clinical Practice | June 9, 2014 | Volume: 4 | Issue: 3 | Pages: 268-269

10.1212/cpj.0000000000000032 | PMID 29473573 Get It

Dementia in MS complicated by coexistent Alzheimer disease
Flanagan, Eoin P. , Knopman, David S. , Keegan, B. Mark , Flanagan, E P

Neurology Clinical Practice | June 9, 2014 | Volume: 4 | Issue: 3 | Pages: 226-230

10.1212/cpj.0000000000000030 | PMID 25110620 Get It

Thyroid fine‐needle aspiration cytology: Performance data of neoplastic and malignant cases as identified from 1558 responses in the ASCP Non‐GYN Assessment program thyroid fine‐needle performance data
Eilers, Stan G., LaPolice, Paula, Mukunyadzi, Perkins , Kapur, Umesh, Spiczka, Amy Wendel, Saleh, Husain A., Nunez, Amberly L., Balachandran, Indra, Clark, Jennifer , Lemon, Larry, Eilers, Stanley G., Shah, Ajay M. , Adeniran, Adebowale

Cancer Cytopathology | June 9, 2014 | Volume: 122 | Issue: 10 | Pages: 745-750

10.1002/cncy.21440 | PMID 24913410 Get It

BACKGROUNDFine‐needle aspiration of the thyroid is a common procedure, with an established role in reducing unnecessary thyroid surgery and identifying neoplasms and malignancies.METHODSThe study evaluated 1558 responses in the American Society for Clinical Pathology (ASCP) Non‐GYN Assessment program of aspirates of thyroid neoplasms and malignancies and placed them into the following groups: group A (target or correct interpretation), group B (incorrect interpretation as a benign thyroid nodule), group C (incorrect interpretation malignant aspirate as thyroid neoplasm), and group D (malignant diagnosis with incorrect interpretation). In clinical practice, responses in groups A, C, and D would lead to surgical excision, whereas responses in group B would not.RESULTSOf a total of 1558 responses, 78.5% of the responses were in group A, 8.5% in group B, 3.75% in group C, and 9.25% in group D. By individual diagnosis, the group rates were 86.5%, 0%, 11%, and 2.5% for anaplastic thyroid carcinoma; 83%, 5.5%, 4.25%, and 7.25% for papillary thyroid carcinoma; 79%, 7%, 6%, and 8% for medullary thyroid carcinoma; 83.5% 6.75%, 0%, and 9.75% for Hürthle cell neoplasm; and 61%, 22%, 0%, and 17% for follicular neoplasm in groups A, B, C, and D respectively.CONCLUSIONSFine‐needle aspiration was effective in diagnosing thyroid neoplasms and malignancies and in separating thyroid nodules into surgical and nonsurgical categories. Data from a large group of cytology professionals showed good performance; however, there is room for improvement, especially in making specific diagnoses. In particular, follicular neoplasm and follicular variant of papillary thyroid carcinoma were challenging diagnoses for participants. Cancer (Cancer Cytopathol) 2014;122:745–750. © 2014 The Authors. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Faculty Opinions recommendation of Improvement in specific function-related quality-of-life concerns after strabismus surgery in nondiplopic adults.
Brodsky, Michael C., Grigorian, Paula

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 9, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718338989.793495767 Get It

OC-030 Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study
Trivedi, PJ, Buuren, H. van, Battezzati, Pm, Floreani, Annarosa , Ponsioen, Cyriel Y. , Poupon, R., Mayo, Marlyn J. , Talwalkar, Jayant A., Burroughs, AK, Nevens, Frederik , Bruns, Tony , Li, KK, Cheung, Angela , Cazagon, N, Franceschet, I., Imam, Mohamad , Pieri, Giulia , Kanwar, Pushpjeet, Lindor, Keith D. , Lammers, Willem J. , Janssen, Harry L.A. , Invernizzi, Pietro , Parés, Albert , Corpechot, Christophe , Mason, Andrew L. , Kowdley, Kris V. , Kumagi, Teru , Lleò, Ana , Caballería, Llorenç , Boonstra, Kirsten , Vries, Esther de , Hansen, Bettina E. , Hirschfield, Gideon M. , Bruns, Tony

Gut | June 9, 2014 | Volume: 63 | Issue: Suppl 1 | Pages: A15-A16

10.1136/gutjnl-2014-307263.30 Get It

Introduction Hepatocellular carcinoma (HCC) is an important but infrequent outcome in primary biliary cirrhosis (PBC). Improved risk evaluation is an important goal for stratified surveillance. Methods Risk-factor analysis of the ‘Global PBC Study Group’ comprising 15 centres across North America and Europe spanning >40-years follow-up was performed using Cox proportional hazards model, logistic regression and Kaplan-Meier estimates (SPSSv21). Results Of 3546 patients with PBC (med. follow-up 8.6 yrs; IQR 4.4–14.1), 131 developed HCC. Excluding those who developed HCC within 12 months of PBC diagnosis (n = 23), median time to HCC was 12.7 yrs (6.9–16.8) and subsequent survival 1.1 yrs. (0.2–2.7). At diagnosis, factors associated with HCC development were male gender (adj. HR: 4.4;1.4–12.2, p = 0.014) and thrombocytopenia (adj. HR: 4.5;1.4–14.8, p = 0.012). Use of ursodeoxycholic acid per-se was not associated with future risk of HCC, but stratification of risk by biochemical response at 12 months was effective by Rotterdam (adj. HR: 8.9;2.1–37.3, P = 0.003), Paris-I (adj. HR: 7.6;2.0–29.0, p = 0.003) or Toronto criteria (HR: 5.6;1.6–18.8, P = 0.006). Five (4.6 vs. 0.2%) and 10-year (13%vs.1.9%) HCC incidence was significantly increased for biochemical non-responders (p = 2.2 × 10 –9 ), and by multivariate analysis non-response remained the only significant risk factor. Conclusion Our uniquely powered cohort allows robust demonstration that 12-month biochemical non-response is associated with an increased risk of developing HCC in PBC. Routine surveillance in those achieving biochemical response is unlikely cost-effective. Disclosure of Interest None Declared.
OC-020 Comparative Effectiveness Of Novel Techniques For Barrett’s Oesophagus (bo) Screening In The Community: A Prospective Randomised Trial
Sami, SS, Dunagan, KT, Johnson, ML, Schlek, CD, Zinsmeister, AR, Song, LM Wong Kee, Kk, Wang, Katzka, D A, Ragunath, Krish , Iyer, PG

Gut | June 9, 2014 | Volume: 63 | Issue: Suppl 1 | Pages: A10.1-A10

10.1136/gutjnl-2014-307263.20 Get It

Introduction BO is the strongest precursor of oesophageal adenocarcinoma. Participation patterns and effectiveness of BO community screening using unsedated transnasal endoscopy (uTNE) is unknown. Feasibility of mobile van screening closer to home is also unknown. We aimed to assess the effectiveness of this technique compared to sedated endoscopy (SE). Methods A population cohort ≥50 years of age, with no history of endoscopic evaluation, was identified from a group of subjects who previously completed a validated symptom questionnaire. Patients were randomised (stratified by age, sex and reflux symptoms) and invited to undergo either uTNE in a mobile research van (muTNE), uTNE in outpatient endoscopy suite (huTNE) or SE. uTNE was performed using a portable oesophagoscope with a disposable sheath. Procedure performance characteristics and validated tolerability scales (0 = none and 10 = severe) were recorded. Results 459 subjects were contacted and 209 (46%) agreed to undergo study procedures (muTNE n = 76, huTNE n = 72, SE n = 61). Baseline characteristics were comparable among the three groups. Participation rates were numerically higher in the unsedated arms (muTNE 47.5%, huTNE 45.7%) than in the SE arm (40.7%) (p = 0.27). Patients with acid reflux symptoms ≥1/week were more likely to participate (odds ratio 2.94, 95% confidence interval 1.47, 5.88). Complete evaluation of the oesophagus was comparable using muTNE (99%), huTNE (96%) and SE (100%) techniques. Successful biopsy acquisition was lower in the muTNE (79%) and huTNE (83%) groups compared to SE (100%) (p = 0.001). Mean duration (minutes) of examination was shorter in the SE arm (4.7) than in muTNE (8.0) and huTNE (8.5) groups (p < 0.001). However, recovery time was much longer for SE (67.3) compared to muTNE (15.5) and huTNE (18.5) techniques (p < 0.001). While overall tolerability for SE was better than muTNE and huTNE (mean score 0.4 vs. 1.9 and 2.2 respectively, p < 0.001), the majority of patients who underwent muTNE and huTNE were willing to undergo the same procedure again in future (79% and 83%, respectively). No serious adverse events were reported. 16 subjects (7.6%) were diagnosed with BO. Conclusion In this first large randomised trial evaluating novel approaches for community screening for BO, unsedated mobile van and clinic screening with TNE was feasible and effective. The patients’ visit was significantly shorter with adequate tolerability, acceptability and safety profiles. Mobile and outpatient techniques may provide a cost-effective alternative to SE for BO screening. Disclosure of Interest S. Sami: None Declared, K. Dunagan: None Declared, M. Johnson: None Declared, C. Schlek: None Declared, A. Zinsmeister: None Declared, L. M. Wong Kee Song: None Declared, K. Wang: None Declared, D. Katzka: None Declared, K. Ragunath Grant/research support from: Olympus (keymed, UK) and Intromed Ltd. (Seoul, South Korea), P. Iyer: None Declared.